Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc’s remdesivir.
The drug baricitinib, branded as Olumiant, cut the median recovery time by about a day when added to remdesivir, compared to patients treated with the antiviral alone, Lilly said.
Remdesivir was granted an emergency use authorization (EUA) in May after trial data showed it helped shorten hospital recovery time by 31%.
Lilly said it plans to discuss the potential for an EAU for baricitinib with the U.S. Food and Drug Administration, based on the results from the trial, which tested more than 1,000 patients.
“As an already approved and available drug, we believe baricitinib could serve as an important additional treatment option as the medical community continues to learn how to best manage patients hospitalized with COVID-19,” said Mizuho analyst Vamil Divan.
The drug, licensed by Lilly from Incyte Corp, could help suppress a potentially lethal immune response to COVID-19 called “cytokine storm”.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.
ENJOY FEEL GOOD, INSPIRING STORIES AND VIDEOS ?
Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.